Spliceosome-Targeted Therapies Induce dsRNA Responses

Charles A Ishak; Helen Loo Yau; Daniel D De Carvalho

doi:10.1016/j.immuni.2020.12.012

Spliceosome-Targeted Therapies Induce dsRNA Responses

Immunity. 2021 Jan 12;54(1):11-13. doi: 10.1016/j.immuni.2020.12.012.

Authors

Charles A Ishak¹, Helen Loo Yau², Daniel D De Carvalho³

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
² Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2M9, Canada. Electronic address: ddecarv@uhnresearch.ca.

PMID: 33440135
DOI: 10.1016/j.immuni.2020.12.012

Abstract

In a recent issue of Cell, Bowling et al. describe a mechanism by which spliceosome-targeted therapies result in intron-containing transcripts that form double-stranded RNAs (dsRNAs), thereby activating tumor antiviral signaling (viral mimicry) and downstream adaptive immunity.

Publication types

Comment

MeSH terms

Adaptive Immunity
Antiviral Agents / pharmacology
RNA, Double-Stranded*
Signal Transduction / drug effects
Spliceosomes*

Substances

Antiviral Agents
RNA, Double-Stranded